Nalaganje...

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Serrao, Erik, Odde, Srinivas, Ramkumar, Kavya, Neamati, Nouri
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2660292/
https://ncbi.nlm.nih.gov/pubmed/19265512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-6-25
Oznake: Označite
Brez oznak, prvi označite!